Jérôme Lambert

机构：Inserm, Université Paris-Est Créteil, Université Paris Cité, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Paris Cardiovascular Research Center, Hôpital Saint-Louis, Institut de recherche Saint-Louis · ORCID：0000-0001-7086-9295

发表论文 335 篇 · 总被引 9126 次 · h-index 51

代表论文

• Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma (2025 · New England Journal of Medicine · 被引 76)
• Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial (2025 · Blood · 被引 39)
• Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results (2025 · Blood · 被引 28)
• Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial (2025 · The Lancet Oncology · 被引 20)
• The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma (2024 · Blood · 被引 16)
• A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a (2025 · Blood · 被引 15)